Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD22 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
NCT04088864Phase 1Completed
- Start
- Jan 2020
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute lymphoblastic leukemia (ALL) and B cell lymphoma (2 arms). Primary endpoints: Rate of successful manufacture of CD22 CAR T cells and Safe dose of CD22-CAR T cells in subjects with R/R B-cell malignancies. Started Jan 2020; status: completed.
02
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT04088864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088864.